Table 1

Clinical feature, treatment, and outcome of intralesional injection of pingyangmycin of the 13 patients with orbital vascular malformations

LocationProptosisVolume of lesion
No.SexAge (year)EyeCourse of disease (months)Presenting symptomDiagnosisMuscle coneQuadrantOrbital apexDosage (mg)Pre (mm)Post (mm)Reduction (mm)Pre (cm3)Post (cm3)Reduction (cm3)Reduction (%)Interval to post imaging (months)Interval to final follow-up (months)
1F38os0.3Slight painVMOuterNNo4.01.50.01.51.70.31.481.621.421.7
2M52od2.0Proptosis, swellingVMInnerNINo4.06.00.55.53.82.51.334.61.621.2
3F39os36Proptosis, swellingCHInnerCYes5.06.00.55.54.51.43.169.02.120.0
4*F16os84Proptosis, swellingCHInnerSYes6.05.52.53.08.86.62.224.54.323.4
5F58od1.0Incidental CT findingCHInnerCYes4.02.00.02.04.70.64.086.415.916.3
6M28os0.8Proptosis, swellingCHInnerCYes4.05.00.05.07.71.46.381.52.12.6
7M36os0.7Proptosis, Valsalva(+)VMInnerNNo6.03.00.03.04.81.83.061.78.89.1
8M16od1.0ProptosisVMInnerTSYes4.05.00.05.06.51.84.872.82.52.5
9F34od120Proptosis, Valsalva(+)VMInnerTSYes2.03.00.03.01.70.51.270.61.92.5
10F48od0.5Slight painVMInnerNSNo4.00.00.00.01.60.21.488.317.217.5
11F42od10Slight fullnessCHInnerCYes4.00.00.00.02.60.42.284.818.918.9
12F21os84Proptosis, strabismusLInner and outerNSYes4.04.00.04.04.00.73.382.613.313.3
13M41os60Proptosis, diplopiaCHInnerCYes4.03.5−1.04.55.11.43.671.93.04.5
  • *Patient underwent a second injection of pingyangmycin during follow-up when an biopsy was performed to study pathological changes due to pingyangmycin treatment; postoperative proptosis (2.5 mm) and volume of this lesion (6.6 cm3) are given as measured after the first injection.

  • C, central; CH, cavernous haemangioma; I, inferior; L, lymphangioma; N, nasal; S, superior; T, temporal; VM, venous malformation.